SEC Form 4 · accession 0001209191-19-015916
Athenex, Inc. · ATNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Manson Fok
Director
Period of report
Feb 28, 2019
Accepted (ET)
Mar 4, 2019 · 6:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001300699
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 1,819,609 | D | ||
| Common StockF1,F2 | holding | — | — | — | 678,880 | I | By Avalon Biomedical (Management) Limited | |
| Common StockF3,F1,F2 | holding | — | — | — | 107,181 | I | By Avalon Polytom (HK) Limited |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F6 | $13.17 | Feb 28, 2019 | A | 10,000 | A | — | Feb 28, 2029 | Common Stock | 10,000 | 10,000 | D |
| Stock Option (Right to Buy) | $4.55 | holding | — | — | — | Jan 2, 2014 | Jan 2, 2023 | Common Stock | 80,000 | 80,000 | D |
| Stock Option (Right to Buy) | $4.55 | holding | — | — | — | May 13, 2014 | May 13, 2023 | Common Stock | 48,000 | 48,000 | D |
| Stock Option (Right to Buy) | $4.55 | holding | — | — | — | Oct 11, 2015 | Oct 11, 2023 | Common Stock | 20,000 | 20,000 | D |
| Stock Option (Right to Buy) | $4.55 | holding | — | — | — | Jun 12, 2016 | Jun 12, 2024 | Common Stock | 40,000 | 40,000 | D |
| Stock Option (Right to Buy) | $7.50 | holding | — | — | — | May 18, 2016 | May 18, 2025 | Common Stock | 48,000 | 48,000 | D |
| Stock Option (Right to Buy) | $9.00 | holding | — | — | — | Oct 17, 2017 | Oct 17, 2025 | Common Stock | 48,000 | 48,000 | D |
| Stock Option (Right to Buy)F4 | $11.00 | holding | — | — | — | — | Jun 13, 2027 | Common Stock | 27,000 | 27,000 | D |
| Stock Option) Right to Buy)F1,F2,F5 | $9.00 | holding | — | — | — | — | Jul 17, 2025 | Common Stock | 54,904 | 54,904 | I |
Explanation of responses
- F1Avalon Biomedical (Management) Limited ("Avalon Biomedical") is an indirect wholly-owned subsidiary of Avalon Global Holdings Limited ("Avalon Global"). Mason Fok, M.B., B.S. ("Dr. Fok"), together with his spouse, own all of the outstanding interests in Sino Glory Developments Limited, which owns 34.63% of the outstanding interests in Avalon Global, and Dr. Fok serves on the board of directors of Avalon Global and has shared voting and dispositive power with respect to the shares held by Avalon Biomedical.
- F2Dr. Fok disclaims beneficial ownership of the reported securities except to the extent, if any, of its or his pecuniary interest therein, and this report shall not be deemed an admission that Dr. Fok is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- F3These shares were acquired pursuant to the terms of a License Agreement dated as of June 29, 2018 by and between Athenex Therapeutics Limited, a wholly-owned subsidiary of Athenex, Inc. ("Athenex") and Avalon Polytom (HK) Limited, a majority-owned affiliate of Avalon Global. The number of shares was determined by dividing $2.0 million by the closing price of Athenex common stock on June 29, 2018.
- F4This option vests in four equal annual installments beginning on June 13, 2018.
- F5This option vests in three equal annual installments beginning on July 17, 2016.
- F6This option vests in four equal annual installments beginning on February 28, 2020.